MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice

Vaccine

Volumn 35, Issue 16, 2017, Pages 2015-2024

  Davtyan, Hayk ^a   Chen, Wesley W ^b   Zagorski, Karen ^a   Davis, Joy ^c   Petrushina, Irina ^c   Kazarian, Konstantin ^a   Cribbs, David H ^c   Agadjanyan, Michael G ^a,c   Blurton Jones, Mathew ^b,c   Ghochikyan, Anahit ^a  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's diseases; Anti tau antibody; DNA epitope vaccine; Tau immunotherapy; Transgenic mice

Indexed keywords

AV 1980D VACCINE; DNA VACCINE; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; TAU PROTEIN; UNCLASSIFIED DRUG; ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; BRAIN TISSUE; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG POTENCY; ELECTROPORATION; FEMALE; FRONTOTEMPORAL DEMENTIA; HELPER CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; TAUOPATHY; TIBIALIS ANTERIOR MUSCLE; VACCINATION; ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE; PATHOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME; WESTERN BLOTTING;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTES; MICE, TRANSGENIC; TAU PROTEINS; TREATMENT OUTCOME; VACCINES, DNA;

EID: 85015376773     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.03.020     Document Type: Article

References (54)

1. [1] Dementia, Fact Sheet. < http://www.who.int/mediacentre/factsheets/fs362/en/>; [April, 2016].
2. [2] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: a report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34 (1984), 939–944.
3. [3] Pike, C.J., Walencewicz, A.J., Glabe, C.G., Cotman, C.W., In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563 (1991), 311–314.
4. [4] Hardy, J., Allsop, D., Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12 (1991), 383–388.
5. [5] Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
6. [6] Price, D.L., Sisodia, S.S., Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med 45 (1994), 435–446.
7. [7] Nikolaev, A., McLaughlin, T., O'Leary, D.D., Tessier-Lavigne, M., APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457 (2009), 981–989.
8. [8] Ballatore, C., Lee, V.M., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8 (2007), 663–672.
9. [9] Jack, C.R. Jr, Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 (2013), 207–216.
10. [10] Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
11. [11] Gerson, J.E., Kayed, R., Formation and propagation of tau oligomeric seeds. Front Neurol, 4, 2013, 93.
12. [12] Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., Tolnay, M., “Prion-like” templated misfolding in tauopathies. Brain Pathol 23 (2013), 342–349.
13. [13] Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T.E., Ma, S., Maloney, S.E., et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80 (2013), 402–414.
14. [14] Frost, B., Diamond, M.I., Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 11 (2010), 155–159.
15. [15] Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 63 (2006), 1459–1467.
16. [16] Kontsekova, E., Zilka, N., Kovacech, B., Novak, P., Novak, M., First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther, 6, 2014, 44.
17. [17] Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 27 (2007), 9115–9129.
18. [18] Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 30 (2010), 16559–16566.
19. [19] Bi, M., Ittner, A., Ke, Y.D., Gotz, J., Ittner, L.M., Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE, 6, 2011, e26860.
20. [20] Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., Rosenmann, H., Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 224 (2010), 472–485.
21. [21] Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F.J., Grosjean, M.E., Zommer, N., et al. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 9 (2012), 397–405.
22. [22] Goni, F., Herline, K., Peyser, D., Wong, K., Ji, Y., Sun, Y., et al. Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation, 10, 2013, 150.
23. [23] Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., Lopez-Deber, M.P., Reis, P., et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS ONE, 8, 2013, e72301.
24. [24] Ghochikyan, A., Davtyan, H., Petrushina, I., Hovakimyan, A., Movsesyan, N., Davtyan, A., et al. Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccines Immunother 9 (2013), 1002–1010.
25. [25] Evans, C.F., Davtyan, H., Petrushina, I., Hovakimyan, A., Davtyan, A., Hannaman, D., et al. Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement 10 (2014), 284–295.
26. [26] Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Cribbs, D.H., et al. The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement 10 (2014), 271–283.
27. [27] Davtyan, H., Hovakimyan, A., Zagorski, K., Davtyan, A., Petrushina, I., Agdashian, D., et al. BTX AgilePulse(TM) system is an effective electroporation device for intramuscular and intradermal delivery of DNA vaccine. Curr Gene Ther 14 (2014), 190–199.
28. [28] Ward, S.M., Himmelstein, D.S., Lancia, J.K., Binder, L.I., Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40 (2012), 667–671.
29. [29] Morfini, G.A., Burns, M., Binder, L.I., Kanaan, N.M., LaPointe, N., Bosco, D.A., et al. Axonal transport defects in neurodegenerative diseases. J Neurosci 29 (2009), 12776–12786.
30. [30] Kanaan, N.M., Morfini, G., Pigino, G., LaPointe, N.E., Andreadis, A., Song, Y., et al. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging 33:826 (2012), e15–e30.
31. [31] Derisbourg, M., Leghay, C., Chiappetta, G., Fernandez-Gomez, F.J., Laurent, C., Demeyer, D., et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep, 5, 2015, 9659.
32. [32] Gamblin, T.C., Berry, R.W., Binder, L.I., Tau polymerization: role of the amino terminus. Biochemistry 42 (2003), 2252–2257.
33. [33] Schindowski, K., Bretteville, A., Leroy, K., Begard, S., Brion, J.P., Hamdane, M., et al. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169 (2006), 599–616.
34. [34] Cribbs, D.H., Ghochikyan, A., Tran, M., Vasilevko, V., Petrushina, I., Sadzikava, N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid. Int Immunol 15 (2003), 505–514.
35. [35] Petrushina, I., Ghochikyan, A., Mktrichyan, M., Mamikonyan, G., Movsesyan, N., Davtyan, H., et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Aβ species in amyloid precursor protein transgenic mice. J Neurosci 27 (2007), 12721–12731.
36. [36] Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., et al. Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci 33 (2013), 4923–4934.
37. [37] Davtyan, H., Zagorski, K., Rajapaksha, H., Hovakimyan, A., Davtyan, A., Petrushina, I., et al. Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Sci Rep, 6, 2016, 28912.
38. [38] Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N.A., Muller, F.J., Loring, J.F., et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A 106 (2009), 13594–13599.
39. [39] Marsh, S.E., Abud, E.M., Lakatos, A., Karimzadeh, A., Yeung, S.T., Davtyan, H., et al. The adaptive immune system restrains Alzheimer's disease pathogenesis by modulating microglial function. Proc Natl Acad Sci U S A 113 (2016), E1316–E1325.
40. [40] Finkelman, F.D., Holmes, J., Katona, I.M., Urban, J.F., Beckmann, M.P., Park, L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Ann Rev Immunol 8 (1990), 303–333.
41. [41] Agadjanyan, M.G., Petrovsky, N., Ghochikyan, A., A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement 11 (2015), 1246–1259.
42. [42] Schroeder, S.K., Joly-Amado, A., Gordon, M.N., Morgan, D., Tau-directed immunotherapy: a promising strategy for treating Alzheimer's disease and other tauopathies. J Neuroimmune Pharmacol 11 (2016), 9–25.
43. [43] Orgogozo, J.M., Gilman, S., Dartigues, J.M., Laurent, B., Puel, M., Kirby, L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61:1 (2003), 46–54.
44. [44] Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., et al. Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248 (2013), 451–456.
45. [45] MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy, K.E., Gluckman, S.J., Bagarazzi, M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178 (1998), 92–100.
46. [46] Ferraro, B., Morrow, M.P., Hutnick, N.A., Shin, T.H., Lucke, C.E., Weiner, D.B., Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53 (2011), 296–302.
47. [47] Graham, B.S., Enama, M.E., Nason, M.C., Gordon, I.J., Peel, S.A., Ledgerwood, J.E., et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS ONE, 8, 2013, e59340.
48. [48] Bolhassani, A., Safaiyan, S., Rafati, S., Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer, 10, 2011, 3.
49. [49] Horowitz, P.M., Patterson, K.R., Guillozet-Bongaarts, A.L., Reynolds, M.R., Carroll, C.A., Weintraub, S.T., et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci 24 (2004), 7895–7902.
50. [50] Kanaan, N.M., Morfini, G.A., LaPointe, N.E., Pigino, G.F., Patterson, K.R., Song, Y., et al. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci 31 (2011), 9858–9868.
51. [51] Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., et al. Human secreted tau increases amyloid-β production. Neurobiol Aging 36 (2015), 693–709.
52. [52] Dai, C.L., Chen, X., Kazim, S.F., Liu, F., Gong, C.X., Grundke-Iqbal, I., et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna) 122 (2015), 607–617.
53. [53] Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2 (2015), 278–288.
54. [54] Castillo-Carranza, D.L., Sengupta, U., Guerrero-Munoz, M.J., Lasagna-Reeves, C.A., Gerson, J.E., Singh, G., et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34 (2014), 4260–4272.